Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter April 12, 2016

The use of a “gray zone” considering measurement uncertainty in pharmacological tests. The serum growth hormone stimulation test as an example

  • Juan Manuel Lazzati EMAIL logo , Verónica Zaidman , Mercedes Maceiras , Alicia Belgorosky and Eduardo Chaler EMAIL logo
  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Plebani M. Harmonization in laboratory medicine: the complete picture. Clin Chem Lab Med 2013;51:741–51.10.1515/cclm-2013-0075Search in Google Scholar PubMed

2. International Vocabulary of Metrology – Basic and General Concepts and Associated Terms – Joint Committee for Guides in Metrology 200:2012.Search in Google Scholar

3. Pater C. The blood pressure “Uncertainty Range”- a pragmatic approach to overcome current diagnostic uncertainties (II). Curr Contr Trials Cardiovasc Med 2006;6:5.10.1186/1468-6708-6-5Search in Google Scholar PubMed PubMed Central

4. Evaluation of measurement data – Guide to the expression of uncertainty in measurement. GUM 1995 with minor corrections. Joint Committee for Guides in Metrology 100:2008.Search in Google Scholar

5. Andersson AM, Orskov H, Ranke MB, Skakkebaek NE. Interpretation of growth hormone provocative tests: comparison of cut-off values in four European laboratories. Eur J Endocrinol 1995;132:340–3.10.1530/eje.0.1320340Search in Google Scholar PubMed

6. Chaler EA, Belgorosky A, Maceiras M, Mendioroz M, Rivarola MA. Between-assay differences in serum growth hormone (GH) measurements: importance in the diagnosis of GH deficiency in childhood. Clin Chem 2001;47:1735–8.10.1093/clinchem/47.9.1735Search in Google Scholar

7. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, et al. Consensus statement on diagnosis and treatment of children with idiopathic short stature. A summary of the growth hormone research society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008;93:4210–7.10.1210/jc.2008-0509Search in Google Scholar PubMed

8. Chaler EA, Ballerini G, Lazzati JM, Maceiras M, Frusti M, Bergada I, et al. Cut-off values of serum growth hormone (GH) in pharmacological stimulation tests (PhTs) evaluated in short-statured children using a chemiluminescent immunometric assay (ICMA) calibrated with the International Recombinant Human GH Standard 98/574. Clin Chem Lab Med 2013;51:e95–7.10.1515/cclm-2012-0505Search in Google Scholar PubMed

9. Boquete HR, Sobrado PG, Fideleff HL, Sequeira AM, Giaccio AV, Suarez MG, et al. Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. J Clin Endocrinol Metab 2003;88:4702–8.10.1210/jc.2003-030412Search in Google Scholar PubMed

10. Savage M, Burrent C, Rosenfeld R. The continuum of growth hormone-IGF-I-axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol 2010;72:721–8.10.1111/j.1365-2265.2009.03775.xSearch in Google Scholar PubMed

Received: 2015-9-30
Accepted: 2016-3-6
Published Online: 2016-4-12
Published in Print: 2016-11-1

©2016 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 25.5.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2015-0954/html
Scroll to top button